This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sobel, M. Articles by Kurland, G. Search for Related Content PubMed PubMed Citation Articles by Sobel, M. Articles by Kurland, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Angina Hazardous Substances DB HEPARIN

Circulation, Vol 63, 300-306, Copyright © 1981 by American Heart Association

ARTICLES

Circulating platelet products in unstable angina pectoris

M Sobel, EW Salzman, GC Davies, RI Handin, J Sweeney, J Ploetz and G Kurland

In 19 patients with unstable angina pectoris at rest, plasma levels of the platelet-derived proteins beta-thromboglobulin and platelet factor 4 were significantly elevated in blood samples obtained during or within 4 hours after episodes of angina, but were usually normal during quiescent intervals. Plasma levels of the arachidonic acid metabolite thromboxane B2 were less clearly related to angina, and there was no association of angina with levels of the coagulation product fibrinopeptide A. This demonstration of an association of platelet activation and secretion with unstable angina pectoris by radioimmunoassay of circulating platelet constituents offers a new approach to assessment of therapy in ischemic heart disease and suggests that agents that alter platelet function should be evaluated in patients with unstable angina.

This article has been cited by other articles:

				A. D. Tselepis, J. A. Goudevenos, A. P. Tambaki, L. Michalis, C. S. Stroumbis, D. C. Tsoukatos, M. Elisaf, and D. A. Sideris Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy Cardiovasc Res, July 1, 1999; 43(1): 183 - 191. [Abstract] [Full Text] [PDF]

				C. Bihour, C. Durrieu-Jais, L. Macchi, C. Poujol, P. Coste, P. Besse, P. Nurden, and A. T. Nurden Expression of Markers of Platelet Activation and the Interpatient Variation in Response to Abciximab Arterioscler. Thromb. Vasc. Biol., February 1, 1999; 19(2): 212 - 219. [Abstract] [Full Text] [PDF]

				C. J. Knight, M. Panesar, C. Wright, D. Clarke, P. S. Butowski, D. Patel, A. Patrineli, K. Fox, and A. H. Goodall Altered Platelet Function Detected by Flow Cytometry : Effects of Coronary Artery Disease and Age Arterioscler. Thromb. Vasc. Biol., October 1, 1997; 17(10): 2044 - 2053. [Abstract] [Full Text]

				M. D. Ozner, Y. S. Ahn, L. L. Horstman, W. Jy, L. Kolodny, and R. J. Myerberg Chronic Platelet Activation and Acute Coronary Syndromes in 13 Middle-Aged Patients Clinical and Applied Thrombosis/Hemostasis, January 1, 1997; 3(1): 46 - 53. [Abstract] [PDF]

				I. Ott, F.-J. Neumann, M. Gawaz, M. Schmitt, and A. Schomig Increased Neutrophil-Platelet Adhesion in Patients With Unstable Angina Circulation, September 15, 1996; 94(6): 1239 - 1246. [Abstract] [Full Text]

				L. Grip, C. Hellekant, I. Herzfeld, K. Malmberg, B. Svane, A. Szamosi, M. Velander, and L. Ryden Coronary Angioplasty in Patients with Unstable Angina, with Special Reference to Preceding Treatment with Antithrombin III and Heparin Clinical and Applied Thrombosis/Hemostasis, April 1, 1996; 2(2): 107 - 115. [Abstract] [PDF]

				J. Hirsh and J. A. Cairns Analytic Reviews : Antithrombotic Tberapy in Acute Myocardial Infarction and Unstable Angina J Intensive Care Med, November 1, 1987; 2(6): 299 - 312. [PDF]

				I. Weinberger, J. Fuchs, Z. Rotenberg, A. Almozlino, H. Joshua, and J. Agmon Circulating Platelet Aggregate Size in Ischemic Heart Disease Angiology, August 1, 1986; 37(9): 676 - 682. [Abstract] [PDF]